Human cytomegalovirus (HCMV) is a widely prevalent human herpesvirus, which, after primary infection, persists in the host for life. In healthy individuals, the virus is well controlled by the HCMV-specific T cell response. A key feature of this persistence, in the face of a normally robust host immune response, is the establishment of viral latency. In contrast to lytic infection, which is characterised by extensive viral gene expression and virus production, long-term latency in cells of the myeloid lineage is characterised by highly restricted expression of viral genes, including UL138 and LUNA. Here we report that both UL138 and LUNA-specific T cells were detectable directly ex vivo in healthy HCMV seropositive subjects and that this response is principally CD4+ T cell mediated. These UL138-specific CD4+ T cells are able to mediate MHC class II restricted cytotoxicity and, importantly, show IFNγ effector function in the context of both lytic and latent infection. Furthermore, in contrast to CD4+ T cells specific to antigens expressed solely during lytic infection, both the UL138 and LUNA-specific CD4+ T cell responses included CD4+ T cells that secreted the immunosuppressive cytokine cIL-10. We also show that cIL-10 expressing CD4+ T-cells are directed against latently expressed US28 and UL111A. Taken together, our data show that latency-associated gene products of HCMV generate CD4+ T cell responses in vivo, which are able to elicit effector function in response to both lytic and latently infected cells. Importantly and in contrast to CD4+ T cell populations, which recognise antigens solely expressed during lytic infection, include a subset of cells that secrete the immunosuppressive cytokine cIL-10. This suggests that HCMV skews the T cell responses to latency-associated antigens to one that is overall suppressive in order to sustain latent carriage in vivo.
References
[1]
Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, et al. (2006) Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis 43: 1143–1151. doi: 10.1086/508173
[2]
Crough T, Khanna R (2009) Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 22: 76–98 Table of Contents. doi: 10.1128/cmr.00034-08
[3]
Jackson SE, Mason GM, Wills MR (2011) Human cytomegalovirus immunity and immune evasion. Virus Research 157: 151–160. doi: 10.1016/j.virusres.2010.10.031
[4]
Wills MR, Carmichael AJ, Sissons JG, editors(2006) Adaptive cellular immunity to human cytomegalovirus. 1st ed. Wymondham: Caister Academic press. 25 p.
[5]
Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, et al. (2002) Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99: 3916–3922. doi: 10.1182/blood.v99.11.3916
[6]
Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR (1994) Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83: 1971–1979.
[7]
Reusser P, Riddell SR, Meyers JD, Greenberg PD (1991) Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78: 1373–1380.
[8]
Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, et al. (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257: 238–241. doi: 10.1126/science.1352912
[9]
Sinclair J (2008) Human cytomegalovirus: Latency and reactivation in the myeloid lineage. J Clin Virol 41: 180–185. doi: 10.1016/j.jcv.2007.11.014
[10]
Sinclair J, Sissons P (2006) Latency and reactivation of human cytomegalovirus. J Gen Virol 87: 1763–1779. doi: 10.1099/vir.0.81891-0
[11]
Mendelson M, Monard S, Sissons P, Sinclair J (1996) Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J Gen Virol 77 (Pt 12) 3099–3102. doi: 10.1099/0022-1317-77-12-3099
[12]
Taylor-Wiedeman J, Sissons P, Sinclair J (1994) Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. Journal of Virology 68: 1597–1604.
[13]
Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH (1991) Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 72 (Pt 9) 2059–2064. doi: 10.1099/0022-1317-72-9-2059
[14]
Mason GM, Poole E, Sissons JG, Wills MR, Sinclair JH (2012) Human cytomegalovirus latency alters the cellular secretome, inducing cluster of differentiation (CD)4+ T-cell migration and suppression of effector function. Proc Natl Acad Sci U S A 109: 14538–14543. doi: 10.1073/pnas.1204836109
[15]
Hahn G, Jores R, Mocarski ES (1998) Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci U S A 95: 3937–3942. doi: 10.1073/pnas.95.7.3937
[16]
Reeves MB, MacAry PA, Lehner PJ, Sissons JGP, Sinclair JH (2005) Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proceedings of the National Academy of Sciences of the United States of America 102: 4140–4145. doi: 10.1073/pnas.0408994102
[17]
Soderberg-Naucler C, Fish KN, Nelson JA (1997) Reactivation of Latent Human Cytomegalovirus by Allogeneic Stimulation of Blood Cells from Healthy Donors. Cell 91: 119–126. doi: 10.1016/s0092-8674(01)80014-3
[18]
Avetisyan G, Aschan J, Hagglund H, Ringden O, Ljungman P (2007) Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 40: 865–869. doi: 10.1038/sj.bmt.1705825
[19]
Barron MA, Gao D, Springer KL, Patterson JA, Brunvand MW, et al. (2009) Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients. Clin Infect Dis 49: 1777–1783. doi: 10.1086/648423
[20]
Elkington R, Walker S, Crough T, Menzies M, Tellam J, et al. (2003) Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 77: 5226–5240. doi: 10.1128/jvi.77.9.5226-5240.2003
[21]
Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, et al. (2005) Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202: 673–685. doi: 10.1084/jem.20050882
[22]
Borysiewicz LK, Hickling JK, Graham S, Sinclair J, Cranage MP, et al. (1988) Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 168: 919–931. doi: 10.1084/jem.168.3.919
[23]
Khan N, Cobbold M, Keenan R, Moss P (2002) Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality and phenotype. J Infect Dis 185: 1025–1034. doi: 10.1086/339963
[24]
Kondo K, Kaneshima H, Mocarski ES (1994) Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci U S A 91: 11879–11883. doi: 10.1073/pnas.91.25.11879
[25]
Kondo K, Mocarski ES (1995) Cytomegalovirus latency and latency-specific transcription in hematopoietic progenitors. Scand J Infect Dis Suppl 99: 63–67.
[26]
Kondo K, Xu J, Mocarski ES (1996) Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc Natl Acad Sci U S A 93: 11137–11142. doi: 10.1073/pnas.93.20.11137
[27]
Bego M, Maciejewski J, Khaiboullina S, Pari G, St. Jeor S (2005) Characterization of an Antisense Transcript Spanning the UL81–82 Locus of Human Cytomegalovirus. J Virol 79: 11022–11034. doi: 10.1128/jvi.79.17.11022-11034.2005
[28]
Goodrum F, Reeves M, Sinclair J, High K, Shenk T (2007) Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 110: 937–945. doi: 10.1182/blood-2007-01-070078
[29]
Jenkins C, Abendroth A, Slobedman B (2004) A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. J Virol 78: 1440–1447. doi: 10.1128/jvi.78.3.1440-1447.2004
[30]
Jenkins C, Garcia W, Abendroth A, Slobedman B (2008) Expression of a human cytomegalovirus latency-associated homolog of interleukin-10 during the productive phase of infection. Virology 370: 285–294. doi: 10.1016/j.virol.2007.09.002
[31]
Jenkins C, Garcia W, Godwin MJ, Spencer JV, Stern JL, et al. (2008) Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection. J Virol 82: 3736–3750. doi: 10.1128/jvi.02173-07
[32]
Reeves MB, Sinclair JH (2010) Analysis of latent viral gene expression in natural and experimental latency models of human cytomegalovirus and its correlation with histone modifications at a latent promoter. J Gen Virol 91: 599–604. doi: 10.1099/vir.0.015602-0
[33]
Tey SK, Goodrum F, Khanna R (2010) CD8+ T-cell recognition of human cytomegalovirus latency-associated determinant pUL138. J Gen Virol 91: 2040–2048. doi: 10.1099/vir.0.020982-0
[34]
Hedge NR, Dunn C, Lewinsohn DM, Jarvis MA, Nelson JA, et al. (2005) Endogenous human cytomegalovirus gB is presented efficiently by MHC II molecules to CD4+ CTL. J Exp Med 202: 1109–1119. doi: 10.1084/jem.20050162
[35]
Elkington R, Shoukry Naglaa H, Walker S, Crough T, Fazou C, et al. (2004) Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. European Journal of Immunology 34: 3216–3226. doi: 10.1002/eji.200425203
[36]
Crompton L, Khan N, Khanna R, Nayak L, Moss PA (2008) CD4+ T cells specific for glycoprotein B from cytomegalovirus exhibit extreme conservation of T-cell receptor usage between different individuals. Blood 111: 2053–2061. doi: 10.1182/blood-2007-04-079863
[37]
Voo KS, Peng G, Guo Z, Fu T, Li Y, et al. (2005) Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res 65: 1577–1586. doi: 10.1158/0008-5472.can-04-2552
[38]
Munz C, Bickham KL, Subklewe M, Tsang ML, Chahroudi A, et al. (2000) Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 191: 1649–1660. doi: 10.1084/jem.191.10.1649
[39]
Marshall NA, Vickers MA, Barker RN (2003) Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol 170: 6183–6189. doi: 10.4049/jimmunol.170.12.6183
[40]
Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8: 523–532. doi: 10.1038/nri2343
[41]
Schwele S, Fischer AM, Brestrich G, Wlodarski MW, Wagner L, et al. (2012) Cytomegalovirus-specific regulatory and effector T cells share TCR clonality–possible relation to repetitive CMV infections. Am J Transplant 12: 669–681. doi: 10.1111/j.1600-6143.2011.03842.x
[42]
Rouse BT, Sarangi PP, Suvas S (2006) Regulatory T cells in virus infections. Immunol Rev 212: 272–286. doi: 10.1111/j.0105-2896.2006.00412.x
[43]
Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345–352. doi: 10.1038/ni1178
[44]
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151–1164.
[45]
Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, et al. (2005) Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 35: 1681–1691. doi: 10.1002/eji.200526189
[46]
Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, et al. (2004) Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 16: 1643–1656. doi: 10.1093/intimm/dxh165
[47]
Goodrum F, Jordan CT, Terhune SS, High K, Shenk T (2004) Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulations. Blood 104: 687–695. doi: 10.1182/blood-2003-12-4344
[48]
Goodrum FD, Jordan CT, High K, Shenk T (2002) Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proc Natl Acad Sci U S A 99: 16255–16260. doi: 10.1073/pnas.252630899
[49]
Cheung AK, Gottlieb DJ, Plachter B, Pepperl-Klindworth S, Avdic S, et al. (2009) The role of the human cytomegalovirus UL111A gene in down-regulating CD4+ T-cell recognition of latently infected cells: implications for virus elimination during latency. Blood 114: 4128–4137. doi: 10.1182/blood-2008-12-197111
[50]
Cheung AK, Abendroth A, Cunningham AL, Slobedman B (2006) Viral gene expression during the establishment of human cytomegalovirus latent infection in myeloid progenitor cells. Blood 108: 3691–3699. doi: 10.1182/blood-2005-12-026682
[51]
Beisser PS, Laurent L, Virelizier JL, Michelson S (2001) Human cytomegalovirus chemokine receptor gene US28 is transcribed in latently infected THP-1 monocytes. J Virol 75: 5949–5957. doi: 10.1128/jvi.75.13.5949-5957.2001
[52]
Powers C, DeFilippis V, Malouli D, Früh K, Shenk TE, et al.. (2008) Cytomegalovirus Immune Evasion Human Cytomegalovirus. Springer Berlin Heidelberg. pp. 333–359.
[53]
Lehner PJ, Wilkinson GW (2001) Cytomegalovirus: from evasion to suppression? Nat Immunol 2: 993–994. doi: 10.1038/ni1101-993
[54]
Miller-Kittrell M, Sparer TE (2009) Feeling manipulated: cytomegalovirus immune manipulation. Virol J 6: 4. doi: 10.1186/1743-422x-6-4
[55]
Loenen WA, Bruggeman CA, Wiertz EJ (2001) Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. Semin Immunol 13: 41–49. doi: 10.1006/smim.2001.0294
[56]
Le Roy E, Muhlethaler-Mottet A, Davrinche C, Mach B, Davignon JL (1999) Escape of human cytomegalovirus from HLA-DR-restricted CD4(+) T-cell response is mediated by repression of gamma interferon-induced class II transactivator expression. J Virol 73: 6582–6589.
[57]
Poole E, Walther A, Raven K, Benedict CA, Mason GM, et al. (2013) The myeloid transcription factor GATA-2 regulates the viral UL144 gene during human cytomegalovirus latency in an isolate-specific manner. J Virol 87: 4261–4271. doi: 10.1128/jvi.03497-12
[58]
Voo KS, Peng G, Guo Z, Fu T, Li Y, et al. (2005) Functional Characterization of EBV-Encoded Nuclear Antigen 1-Specific CD4+ Helper and Regulatory T Cells Elicited by In vitro Peptide Stimulation. Cancer Res 65: 1577–1586. doi: 10.1158/0008-5472.can-04-2552
[59]
Swain SL, McKinstry KK, Strutt TM (2012) Expanding roles for CD4 T cells in immunity to viruses. Nat Rev Immunol 12: 136–148. doi: 10.1038/nri3152
[60]
Tang Q, Bluestone JA, Kang S-M (2012) CD4+Foxp3+ regulatory T cell therapy in transplantation. Journal of Molecular Cell Biology 4: 11–21. doi: 10.1093/jmcb/mjr047
[61]
Savage PA, Malchow S, Leventhal DS (2013) Basic principles of tumor-associated regulatory T cell biology. Trends in immunology 34: 33–40. doi: 10.1016/j.it.2012.08.005
[62]
Humphreys IR, de Trez C, Kinkade A, Benedict CA, Croft M, et al. (2007) Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands. J Exp Med 204: 1217–1225. doi: 10.1084/jem.20062424
[63]
Jones M, Ladell K, Wynn KK, Stacey MA, Quigley MF, et al. (2010) IL-10 restricts memory T cell inflation during cytomegalovirus infection. J Immunol 185: 3583–3592. doi: 10.4049/jimmunol.1001535
[64]
Hall CH, Kassel R, Tacke RS, Hahn YS (2010) HCV+ hepatocytes induce human regulatory CD4+ T cells through the production of TGF-beta. PLoS One 5: e12154. doi: 10.1371/journal.pone.0012154
[65]
Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, et al. (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212: 28–50. doi: 10.1111/j.0105-2896.2006.00420.x
Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, et al. (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737–742. doi: 10.1038/39614
[68]
Kawamura K, Kadowaki N, Kitawaki T, Uchiyama T (2006) Virus-stimulated plasmacytoid dendritic cells induce CD4+ cytotoxic regulatory T cells. Blood 107: 1031–1038. doi: 10.1182/blood-2005-04-1737
[69]
Avdic S, Cao JZ, Cheung AK, Abendroth A, Slobedman B (2011) Viral interleukin-10 expressed by human cytomegalovirus during the latent phase of infection modulates latently infected myeloid cell differentiation. J Virol 85: 7465–7471. doi: 10.1128/jvi.00088-11
[70]
Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, et al. (1996) The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70: 7569–7579.
[71]
Chomczynski P, Mackey K (1995) Short technical reports. Modification of the TRI reagent procedure for isolation of RNA from polysaccharide- and proteoglycan-rich sources. Biotechniques 19: 942–945.
[72]
Reeves MB, Coleman H, Chadderton J, Goddard M, Sissons JG, et al. (2004) Vascular endothelial and smooth muscle cells are unlikely to be major sites of latency of human cytomegalovirus in vivo. J Gen Virol 85: 3337–3341. doi: 10.1099/vir.0.80285-0
[73]
Poole E, McGregor Dallas SR, Colston J, Joseph RS, Sinclair J (2011) Virally induced changes in cellular microRNAs maintain latency of human cytomegalovirus in CD34(+) progenitors. J Gen Virol 92: 1539–1549. doi: 10.1099/vir.0.031377-0
